ATE420666T1 - Radioaktiv markierte nanoteilchen - Google Patents

Radioaktiv markierte nanoteilchen

Info

Publication number
ATE420666T1
ATE420666T1 AT06764967T AT06764967T ATE420666T1 AT E420666 T1 ATE420666 T1 AT E420666T1 AT 06764967 T AT06764967 T AT 06764967T AT 06764967 T AT06764967 T AT 06764967T AT E420666 T1 ATE420666 T1 AT E420666T1
Authority
AT
Austria
Prior art keywords
radioactive labeled
labeled nanoparticles
nanoparticles
radiolabelled
radiolabelled nanoparticles
Prior art date
Application number
AT06764967T
Other languages
English (en)
Inventor
Paul Beer
Michael Lankshear
Hema Dattani
Alex Jackson
Michelle Avory
Original Assignee
Ge Healthcare Ltd
Univ Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd, Univ Oxford filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of ATE420666T1 publication Critical patent/ATE420666T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Glass Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06764967T 2005-07-15 2006-07-14 Radioaktiv markierte nanoteilchen ATE420666T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0514513.1A GB0514513D0 (en) 2005-07-15 2005-07-15 Particulate agents

Publications (1)

Publication Number Publication Date
ATE420666T1 true ATE420666T1 (de) 2009-01-15

Family

ID=34897245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06764967T ATE420666T1 (de) 2005-07-15 2006-07-14 Radioaktiv markierte nanoteilchen

Country Status (9)

Country Link
US (1) US20090110634A1 (de)
EP (1) EP1919517B1 (de)
JP (1) JP5037507B2 (de)
CN (1) CN101222943B (de)
AT (1) ATE420666T1 (de)
DE (1) DE602006004886D1 (de)
ES (1) ES2320805T3 (de)
GB (1) GB0514513D0 (de)
WO (1) WO2007010211A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101862463A (zh) * 2010-06-17 2010-10-20 复旦大学 一种18f标记纳米粒子的制备方法及其应用
US9011735B2 (en) 2010-12-30 2015-04-21 Ut-Battelle, Llc Volume-labeled nanoparticles and methods of preparation
KR101388238B1 (ko) 2013-04-17 2014-04-23 한국원자력연구원 테크네튬-99엠이 표지된 금 나노입자-금결합 펩타이드 복합체 제조 방법, 그 방법에 의해 제조된 복합체 및 이의 용도
KR20250074713A (ko) 2023-11-15 2025-05-28 주식회사 레이메드 방사성 테크네튬-99엠 표지 금속나노입자를 포함하는 췌장암 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818199B1 (en) * 1994-07-29 2004-11-16 James F. Hainfeld Media and methods for enhanced medical imaging
DE19933346A1 (de) * 1999-07-16 2001-01-18 Aventis Res & Tech Gmbh & Co Stabile radioaktiv markierte Nanopartikel, Verfahren zur Herstellung und ihrer Verwendung
US6689338B2 (en) * 2000-06-01 2004-02-10 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
AUPR113100A0 (en) * 2000-10-30 2000-11-23 Australian National University, The Radio-labelled ferrite particles and methods for the manufacture and use thereof
US20040146460A1 (en) * 2001-07-17 2004-07-29 Salafsky Joshua S Design of labels for detection with a surface-seletive nonlinear optical technique
US7695738B2 (en) * 2003-02-19 2010-04-13 Academia Sinica Carbohydrate encapsulated nanoparticles
US20070031327A1 (en) * 2003-06-03 2007-02-08 Luzzi David E Nanoradiopharmaceuticals and methods of use
JP5398982B2 (ja) * 2004-05-24 2014-01-29 ミダテック リミテッド Ｒｎａリガンドを含むナノ粒子

Also Published As

Publication number Publication date
WO2007010211A1 (en) 2007-01-25
JP5037507B2 (ja) 2012-09-26
JP2009501332A (ja) 2009-01-15
ES2320805T3 (es) 2009-05-28
EP1919517B1 (de) 2009-01-14
DE602006004886D1 (de) 2009-03-05
CN101222943A (zh) 2008-07-16
EP1919517A1 (de) 2008-05-14
US20090110634A1 (en) 2009-04-30
CN101222943B (zh) 2013-04-10
GB0514513D0 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
IL181529A (en) A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug
EP1896073A4 (de) Anti-il-23-antikörper, zusammensetzungen, verfahren und verwendung
EP1971366A4 (de) Menschliche anti-il-23-antikörper, zusammensetzungen, verfahren und verwendungen
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
EP2102238A4 (de) Cd44-antikörper
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
AR088405A2 (es) Proceso de sombreado y composicion de sombreado que comprende una ftalocianina
CR20150102A (es) Anticuerpos que se unen a il-4 y/o il-13 (divisional 2)
PT2499165T (pt) Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas
WO2015073746A3 (en) 18f labeling of proteins using sortases
GT200500298A (es) Formulaciones de anticuerpos
HN2006015949A (es) Anticuerpos de p-caderina
BRPI0810332A2 (pt) "politioéter envolvido com amina/hidroxi"
EP2061808A4 (de) Influenza-antikörper, zusammensetzungen und zugehörige verfahren
MX2010001955A (es) Enlazadores polimericos que contienen porciones de disulfuro-piridilo.
EP2519542A4 (de) Anti-cdh3-antikörper und ihre verwendung
WO2010000409A3 (en) Compounds and processes for production of radiopharmaceuticals
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
NO20074277L (no) Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer
TW200738271A (en) Methods of making radiolabeled tracers and precursors thereof
UY30596A1 (es) Marcacion con fluor radioactivo
CY1113022T1 (el) Ακτινoφαρμακευτικες συνθεσεις οι οποιες περιεχουν πολυσακχαριτες εμβολιασμενους με πολυαμιδια
ATE420666T1 (de) Radioaktiv markierte nanoteilchen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties